Patents Assigned to Mochida Pharmaceutical Co., Ltd.
  • Patent number: 10399945
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 3, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko Saitoh, Hiroshi Nagasue
  • Publication number: 20190231731
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shigeru KIMURA, Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA
  • Publication number: 20190209260
    Abstract: [Problem] An adhesion-preventing material having a high adhesion-preventing effect has been demanded. [Solution] An adhesion-preventing material including a sterilized biocompatible sponge-like laminate, wherein the sponge-like laminate comprises a sponge-like first layer and a sponge-like second layer each of which is at least partially crosslinked with a curing agent and comprises a low-endotoxin alginic acid monovalent metal salt, the alginic acid monovalent metal salt in the first layer has a weight average molecular weight of 10,000 to 2,000,000, the alginic acid monovalent metal salt in the second layer has a weight average molecular weight of 1,000 to 1,000,000, the weight average molecular weights are measured by a GPC-MALS method after a decrosslinking treatment, and the weight average molecular weight of the alginic acid monovalent metal salt in the first layer is higher than that in the second layer.
    Type: Application
    Filed: July 13, 2017
    Publication date: July 11, 2019
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventors: Taichi ITO, Seiichi OHTA, Norihiro KOKUDO, Mitsuko ISAJI, Satoshi SHIMIZU
  • Publication number: 20190167802
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 6, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA, Daichi TANAKA
  • Publication number: 20190083678
    Abstract: A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [wherein R1 and R2 independently represent a hydrogen atom or a group represented by formula: —COCH(NH2)—(CH2)4—NH2, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 21, 2019
    Applicants: Tazuke Kofukai, Mochida Pharmaceutical Co., Ltd.
    Inventors: Yoshihisa SUZUKI, Masao TANIHARA, Mitsuko ISAJI
  • Publication number: 20190071441
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Application
    Filed: November 6, 2018
    Publication date: March 7, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • Patent number: 10208010
    Abstract: The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide having excellent TRPV1 antagonistic activity, a drug and a pharmaceutical composition containing this crystal, and a method for producing the crystal. The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide that is excellent in at least one feature selected from the group consisting of storage stability, photostability and thermodynamic stability, that can be preferably obtained with industrially high reproducibility, yield and purity, and that is useful as a crystal of an active pharmaceutical ingredient.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: February 19, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventor: Tsutomu Satoh
  • Patent number: 10201531
    Abstract: The present invention provides a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. A compound having Nrf2 activation ability is provided by the present invention.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 12, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko Saitoh, Tomoyuki Kamino, Motoi Nakahara
  • Publication number: 20190023657
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Application
    Filed: September 21, 2018
    Publication date: January 24, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko SAITOH, Hiroshi NAGASUE
  • Patent number: 10174025
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 8, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu Satoh, Takashi Kudoh, Tetsuo Iwama
  • Publication number: 20180369185
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Application
    Filed: August 29, 2018
    Publication date: December 27, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato FUJII, Motoo YAMAGATA
  • Publication number: 20180346436
    Abstract: The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide having excellent TRPV1 antagonistic activity, a drug and a pharmaceutical composition containing this crystal, and a method for producing the crystal. The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide that is excellent in at least one feature selected from the group consisting of storage stability, photostability and thermodynamic stability, that can be preferably obtained with industrially high reproducibility, yield and purity, and that is useful as a crystal of an active pharmaceutical ingredient.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventor: Tsutomu SATOH
  • Publication number: 20180338921
    Abstract: The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.
    Type: Application
    Filed: September 6, 2016
    Publication date: November 29, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shuichi ENDO, Naoya YOSHIOKA
  • Patent number: 10105340
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Ton or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: October 23, 2018
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Patent number: 10092536
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: October 9, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato Fujii, Motoo Yamagata
  • Patent number: 10058528
    Abstract: Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatis (NASH).
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 28, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Kiyoshi Mizuguchi, Tsuyoshi Harada, Atsushi Osada, Hiroyuki Kawano, Masayuki Ichioka
  • Publication number: 20180237537
    Abstract: The present invention provides anti-presepsin polyclonal antibodies specifically binding to a peptide comprising an amino acid sequence of SEQ ID NO: 1. As a result, anti-presepsin polyclonal antibodies which have less variation in measured values between lot-to-lot differences of antibodies compared to S68 antibodies and thus suitable anti-presepsin polyclonal antibodies for presepsin measurement are provided.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 23, 2018
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon SHIRAKAWA
  • Patent number: 10054585
    Abstract: Methods for detecting respiratory infection associated with bacterial infection are described, in which the values of soluble CD14 antigen subtype (“sCD14-ST”) in the urine sample can be used to select a patient with a respiratory infection to whom antibiotic can be beneficially administered. The methods of this disclosure can also be used to determine the timing for ending administration of the antibiotic to the patient with respiratory infection associated with bacterial infection.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 21, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Publication number: 20180228776
    Abstract: The present invention provides a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. A compound having Nrf2 activation ability is provided by the present invention.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko SAITOH, Tomoyuki KAMINO, Motoi NAKAHARA
  • Publication number: 20180201688
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 19, 2018
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon SHIRAKAWA